Nanogen Revenue Down in Third Quarter; Shareholders to Vote on Epoch Merger Soon | GenomeWeb

This past week Nanogen reported third-quarter revenue of $1.1 million, flat with its second-quarter results and down from $1.7 million in the comparable period a year ago. Product revenue for the quarter also declined to $671,000 from $752,000 in the third quarter of 2003.

The decline marked yet another quarter of shrinking revenue for the microarray-based diagnostics instrument maker, which is in the process of diversifying its product offerings in an effort to quickly add to its top line.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.